DOCSLIB.ORG

Clindamycin and Rifampicin Combination Therapy for Hidradenitis Suppurativa C.O

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clindamycin and Rifampicin Combination Therapy for Hidradenitis Suppurativa C.O CONCISE COMMUNICATION DOI 10.1111/j.1365-2133.2006.07155.x Clindamycin and rifampicin combination therapy for hidradenitis suppurativa C.O. Mendonc¸a and C.E.M. Griffiths The Dermatology Centre, Hope Hospital, The University of Manchester, Salford, Manchester M6 8HD, U.K. Summary Correspondence Background Hidradenitis suppurativa (HS) is a chronic inflammatory condition C.E.M. Griffiths. affecting apocrine gland-bearing areas of the skin. There is currently no satisfac- E-mail: christopher.griffi[email protected] tory treatment. Objectives To assess the efficacy of a 10-week course of combination clindamycin Accepted for publication 21 October 2005 300 mg twice daily and rifampicin 300 mg twice daily in the treatment of HS. Methods Patients who had received combination therapy with clindamycin and rif- Key words ampicin for HS at one U.K. Dermatology Centre between the years 1998 and clindamycin, combination therapy, hidradenitis 2003 were identified from pharmacy records. Their records were analysed retro- suppurativa, rifampicin spectively. Conflicts of interest Results Fourteen patients with HS had received treatment with combination ther- None declared. apy. Eight of these patients achieved remission and a further two achieved remis- sion when minocycline was substituted for clindamycin. Four patients were unable to tolerate therapy. Conclusions This small retrospective study indicates that combination therapy with clindamycin and rifampicin may be effective for HS. However, there is a need for a placebo-controlled trial. Hidradenitis suppurativa (HS), a chronic disease manifested by 300 mg twice daily and clindamycin 300 mg twice daily recurrent abscesses, sinus tracts and scarring, is associated with between 1998 and 2003. The duration of disease ranged from high morbidity. HS arises most commonly, but not exclu- 2 to 30 years (mean 10Æ5). All patients had previously sively, from apocrine gland-bearing areas. The disease begins received other systemic therapies including tetracycline, isotre- after puberty, when apocrine glands in the axillae and perineal tinoin and flucloxacillin, or had been treated surgically region are fully formed, and can occasionally persist into the (Table 1). seventh decade. Staphylococcus aureus and S. epidermidis are patho- 1 gens most frequently found in early lesions of HS. Results Treatment of HS is, in general, unsatisfactory. Surgical exci- sion can result in a cosmetically unacceptable result and does Eight patients (four women and four men) achieved complete not preclude recurrence.2 The combination of oral rifampicin remission of HS of between 1 and 4 years after only one 300 mg twice daily and clindamycin 300 mg twice daily for course of treatment, and a further two patients achieved 10 weeks has been shown to be effective for other follicular remission after substituting minocycline (100 mg daily) for occlusion disorders such as folliculitis decalvans.3,4 Rifampicin clindamycin because of transient diarrhoea. These 10 patients is highly soluble and can sterilize staphylococcal abcesses.5 have not subsequently relapsed. Six responders had perineal However, the emergence of resistance when rifampicin is used involvement only; one perineum, axillae and neck; and three as monotherapy is problematic. Clindamycin was first intro- perineum and axillae only. Four patients were unable to com- duced in the 1970s and several studies have assessed the efficacy plete the course of treatment because of diarrhoea and were of topical clindamycin for HS.6,7 At the Dermatology Centre, not willing to change therapy. Hope Hospital (Manchester, U.K.), we performed a retrospec- tive review of patients with HS who had received 10 weeks of Discussion combination therapy with rifampicin and clindamycin. Therapy of HS is often frustrating and relapses are common. Patients and methods Our open, retrospective study demonstrates that combination therapy with rifampicin and clindamycin appears to be effect- Fourteen patients (nine women and five men) with HS had ive in the treatment of HS in those patients who are able to received 10 weeks of combination therapy with rifampicin tolerate the side-effects. Treatment options include oral Ó 2006 British Association of Dermatologists • British Journal of Dermatology 2006 154, pp977–978 977 978 Hidradenitis suppurativa therapy, C.O. Mendonc¸a and C.E.M. Griffiths Table 1 Patient demographics and prior therapies Patient Age (years)/sex Disease duration(years) Affected area Prior therapy Remission 1 26/F 4 Axillae, breast ery, min, dian N 2 32/F 5 Axillae fluc N 3 37/M 2Æ5 Axillae, perineal lym N 4 64/F 6 Perineal ery Y 5 51/F 10 Perineal ery Y 6 56/M 14 Perineal fluc, pen, isot Y 7 29/F 10 Axillae, perineal ery, isot Y 8 20/M 3 Perineal ery Y 9 24/F 2 Axillae, perineal ery, min, fluc, dian Y 10 39/M 9 Axillae, perineal oxytet Y 11 37/F 17 Axillae, perineal, neck top clind, amp, exc, isot Y/M 12 47/F 30 Perineal isot, cef, min N 13 54/F 25 Perineal ery, top clind Y/M 14 47/M 10 Perineal ery Y ery, erythromycin; min, minocycline; dian, DianetteÒ (co-cyprindiol); fluc, flucloxacillin; lym, lymecycline; pen, penicillin; isot, isotretin- oin; oxytet, oxytetracycline; top clind, topical clindamycin; amp, ampicillin; exc, excision; cef, cefalexin; Y, yes; N, no; Y/M, yes following substitution of minocycline for clindamycin. contraceptives,8 isotretinoin,9 cyproterone acetate,10 acitretin11 2 Harrison BJ, Mudge M, Hughes LE. Recurrence after surgical treat- and long-term antibiotics as used for treatment of acne. The ment of hidradenitis supurativa. BMJ 1987; 294:487–9. effect of topical clindamycin has been shown to be as effective 3 Brooke RCC, Griffiths CEM. Folliculitis decalvans. Clin Exp Dermatol 2001; 26:120–2. as oral tetracycline in HS.6,7 There are recent reports of the 4 Powell JJ, Dawber RPR, Gatter K. Folliculitis decalvans including use of infliximab in the treatment of HS although the long- tufted folliculitis: clinical, histological and therapeutic findings. Br J 12,13 term risks of therapy are unknown. The outcomes of rif- Dermatol 1999; 140:328–33. ampicin/clindamycin combination therapy appear to be better 5 Lorber B. Rifampicin in the treatment of chronic granulomatous than those in studies with isotretinoin when used for HS.9 disease (Letter). N Engl J Med 1980; 303:111. Furthermore, this combination appears to be most effective in 6 Jemec GBE, Wendelboe P. Topical clindamycin versus systemic tet- those patients who have mainly perineal involvement. A 10- racycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 1998; 39:971–4. week course of combination therapy is a relatively low-cost 7 Clemmenson OJ. Topical treatment of hidradenitis suppurativa effective option. Patients should be warned to stop taking the with clindamycin. Int J Dermatol 1983; 22:325–8. combination if they develop diarrhoea as clindamycin is asso- 8 Mortimer PS, Dawber RPR, Gales MA et al. Mediation of hidradeni- ciated with the development of Clostridium difficile colitis. Rif- tis suppurativa by androgens. BMJ 1996; 292:245–8. ampicin is a good antibiotic against C. difficile; this and the 9 Jemec GBE. Long-term results of isotretinoin in the treatment of relatively young age group of the patients may explain why C. 68 patients with hidradenitis suppurativa. J Am Acad Dermatol 1999; difficile-induced diarrhoea was not encountered, although those 41:658. 10 Sawers RS, Randall VA, Ebling FJG. Control of hidradenitis suppu- subjects who developed diarrhoea were not screened for C. rativa in women using combined antiandrogen (cyproterone acet- difficile. However, if diarrhoea occurs clindamycin can be sub- ate) and oestrogen therapy. Br J Dermatol 1986; 115:269–74. stituted by minocycline 100 mg daily to prevent resistance. 11 Hogan DJ, Light MJ. Successful treatment of hidradenitis suppurati- We recommend review of patients after 4 weeks of therapy va with acitretin. J Am Acad Dermatol 1988; 19:355–6. and monitoring of liver function tests and full blood count at 12 Sullivan TP, Welsh E, Kerdel FA et al. Infliximab for hidradenitis baseline, 4 weeks and end of treatment. suppurativa. Br J Dermatol 2003; 149:1046–9. These promising results indicate the need for a randomized, 13 Lebwohl B, Sapadin AN. Infliximab for the treatment of hidradeni- tis suppurativa. J Am Acad Dermatol 2003; 49 (Suppl. 5):S275–6. controlled trial of this combination therapy for HS. References 1 Jemec GBE, Faber M, Gutschik E, Wendelboe P. The bacteriology of hidradenitis suppurativa. Dermatology 1996; 193:203–6. Ó 2006 British Association of Dermatologists • British Journal of Dermatology 2006 154, pp977–978.
Load more

Recommended publications
  • Ceftazidime for Injection) PHARMACY BULK PACKAGE – NOT for DIRECT INFUSION
    PRESCRIBING INFORMATION FORTAZ® (ceftazidime for injection) PHARMACY BULK PACKAGE – NOT FOR DIRECT INFUSION To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibacterial drug for parenteral administration. It is the pentahydrate of pyridinium, 1-[[7-[[(2-amino-4­ thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1­ azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6α,7β(Z)]]. It has the following structure: The molecular formula is C22H32N6O12S2, representing a molecular weight of 636.6. FORTAZ is a sterile, dry-powdered mixture of ceftazidime pentahydrate and sodium carbonate. The sodium carbonate at a concentration of 118 mg/g of ceftazidime activity has been admixed to facilitate dissolution. The total sodium content of the mixture is approximately 54 mg (2.3 mEq)/g of ceftazidime activity. The Pharmacy Bulk Package vial contains 709 mg of sodium carbonate. The sodium content is approximately 54 mg (2.3mEq) per gram of ceftazidime. FORTAZ in sterile crystalline form is supplied in Pharmacy Bulk Packages equivalent to 6g of anhydrous ceftazidime. The Pharmacy Bulk Package bottle is a container of sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous use. THE PHARMACY BULK PACKAGE IS NOT FOR DIRECT INFUSION, FURTHER DILUTION IS REQUIRED BEFORE USE.
    [Show full text]
  • RIFAMPICIN Productinformation Sigma Prod
    RIFAMPICIN ProductInformation Sigma Prod. No. R3501 CH3 CH3 CAS NUMBER: 13292-46-1 HO SYNONYMS: Tubocin; Sinerdol; Rimactan; L-5103; Dione-21 Acetate; Archidyn; Arficin; 3-(4- CH3 O O OH O Methylpiperazinyliminomethyl)-rifamycin SV; NSC 113926; C OH OH CH 1 2 3 H C Rifampin ; Rifaldazine; Rifamycin AMP H3C 3 O NH H3C PHYSICAL PROPERTIES: CH3 N CH N Appearance: Orange-brown to red-brown powder.3 O OH N Molecular formula: C43H58N4O12 O Molecular weight: 823.0 O CH3 CH3 EmM (max absorbance, phosphate buffer, pH 7.38): 33.20 (237 nm); 32.10 (255 nm); 27.00 (334 nm); 15.40 (475 nm)2,4 pKa (in water):1.7 (4-hydroxyl group), 7.9 (4-piperazine nitrogen); in methylcellosolve-water (4:1): 3.6 (4- hydroxyl group), 6.7 (3-piperazine nitrogen)4 pI (in water): 4.84 25° 4 Optical rotation: [α]D =+10.6° (c=0.5% in CDCl3) Melting point: 183-188°C (dec.)2,4 METHOD OF PREPARATION: Methods of preparation have been reported.4,5 The NMR, UV, IR, Mass spectra, Thin-Layer chromatography and HPLC methods of detection have been reported.4,5,6 A colorimetric test for identification was reported.4 STABILITY / STORAGE: Rifampicin (Rif) should be stable for at least two years when stored desiccated at -20°C and protected from light.3 Rif is stable as a solid at temperatures up to 70EC.4 SOLUBILITY / SOLUTION STABILITY: Rif is soluble in dimethylsulfoxide (~100mg/mL), dimethylformamide, methanol (16 mg/ml, 25EC), chloroform (349 mg/ml, 25°C), ethyl acetate (108 mg/ml, 25°C), and acetone (14 mg/ml, 25°C).4,6,7,8,9 Rif is slightly soluble in water at 25°C: 2.5 mg/ml, pH 7.3; 1.3 mg/ml, pH 4.3; and in 95% ethanol (∼10 mg/mL).4 Rif is soluble at 37°C: in 0.1 N HCl, 200 mg/ml and in phosphate buffer pH 7.4, 9.9 mg/ml.4 R3501 Page 1 of 4 03/28/97 - ARO RIFAMPICIN Sigma Prod.
    [Show full text]
  • PROCUR Why Procur Has Been Prescribed for You
    Consumer Medicine Information Ask your doctor if you have any questions about PROCUR why Procur has been prescribed for you. Cyproterone acetate 50 mg and 100 mg tablets This medicine is available only with a doctor's prescription. What is in this leaflet Before you take Procur Please read this leaflet carefully before you start taking Procur When you must not take it This leaflet answers some common questions about Procur. It does not contain all the available Do not take Procur if you have an allergy to: information. It does not take the place of talking • any medicine containing cyproterone acetate to your doctor or pharmacist. • any of the ingredients listed at the end of this leaflet All medicines have risks and benefits. Your doctor has weighed the risks of you taking Procur against Some of the symptoms of an allergic reaction may the benefits they expect it will have for you. include: • difficulty in breathing or wheezing If you have any concerns about taking this • shortness of breath medicine, ask your doctor or pharmacist. • swelling of the face, tongue, lips, or other parts of the body Keep this leaflet with the medicine. You may • hives on the skin, rash, or itching need to read it again. Do not take Procur if: What Procur is used for • you are allergic to cyproterone acetate or any other ingredient listed at the end of this leaflet Procur tablets contain the active ingredient • you are pregnant cyproterone acetate. Cyproterone acetate is an • you are breastfeeding antiandrogen. It works by blocking the actions of • you suffer from liver diseases (including sex hormones (androgens) that are produced previous or existing liver tumours, Dubin- mainly in men but also, to a lesser extent in Johnson syndrome or Rotor syndrome) women.
    [Show full text]
  • 209627Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 209627Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review Reviewers of Multi-Disciplinary Review and Evaluation SECTIONS OFFICE/ AUTHORED/ ACKNOWLEDGED/ DISCIPLINE REVIEWER DIVISION APPROVED Mark Seggel, Ph.D. OPQ/ONDP/DNDP2 Authored: Section 4.2 Digitally signed by Mark R. Seggel -S CMC Lead DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, cn=Mark R. Signature: Mark R. Seggel -S Seggel -S, 0.9.2342.19200300.100.1.1=1300071539 Date: 2018.08.08 16:29:15 -04'00' Frederic Moulin, DVM, PhD OND/ODE3/DBRUP Authored: Section 5 Pharmacology/ Digitally signed by Frederic Moulin -S Toxicology DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, Reviewer Signature: Frederic Moulin -S 0.9.2342.19200300.100.1.1=2001708658, cn=Frederic Moulin -S Date: 2018.08.08 15:26:57 -04'00' Kimberly Hatfield, PhD OND/ODE3/DBRUP Approved: Section 5 Pharmacology/ Toxicology Digitally signed by Kimberly P. Hatfield -S DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, Team Leader Signature: Kimberly P. Hatfield -S 0.9.2342.19200300.100.1.1=1300387215, cn=Kimberly P. Hatfield -S Date: 2018.08.08 14:56:10 -04'00' Li Li, Ph.D. OCP/DCP3 Authored: Sections 6 and 17.3 Clinical Pharmacology Dig ta ly signed by Li Li S DN c=US o=U S Government ou=HHS ou=FDA ou=People Reviewer cn=Li Li S Signature: Li Li -S 0 9 2342 19200300 100 1 1=20005 08577 Date 2018 08 08 15 39 23 04'00' Doanh Tran, Ph.D.
    [Show full text]
  • Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii
    ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org).
    [Show full text]
  • Drug Delivery Systems on Leprosy Therapy: Moving Towards Eradication?
    pharmaceutics Review Drug Delivery Systems on Leprosy Therapy: Moving Towards Eradication? Luíse L. Chaves 1,2,*, Yuri Patriota 2, José L. Soares-Sobrinho 2 , Alexandre C. C. Vieira 1,3, Sofia A. Costa Lima 1,4 and Salette Reis 1,* 1 Laboratório Associado para a Química Verde, Rede de Química e Tecnologia, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, 4050-313 Porto, Portugal; [email protected] (A.C.C.V.); slima@ff.up.pt (S.A.C.L.) 2 Núcleo de Controle de Qualidade de Medicamentos e Correlatos, Universidade Federal de Pernambuco, Recife 50740-521, Brazil; [email protected] (Y.P.); [email protected] (J.L.S.-S.) 3 Laboratório de Tecnologia dos Medicamentos, Universidade Federal de Pernambuco, Recife 50740-521, Brazil 4 Cooperativa de Ensino Superior Politécnico e Universitário, Instituto Universitário de Ciências da Saúde, 4585-116 Gandra, Portugal * Correspondence: [email protected] (L.L.C.); shreis@ff.up.pt (S.R.) Received: 30 October 2020; Accepted: 4 December 2020; Published: 11 December 2020 Abstract: Leprosy disease remains an important public health issue as it is still endemic in several countries. Mycobacterium leprae, the causative agent of leprosy, presents tropism for cells of the reticuloendothelial and peripheral nervous system. Current multidrug therapy consists of clofazimine, dapsone and rifampicin. Despite significant improvements in leprosy treatment, in most programs, successful completion of the therapy is still sub-optimal. Drug resistance has emerged in some countries. This review discusses the status of leprosy disease worldwide, providing information regarding infectious agents, clinical manifestations, diagnosis, actual treatment and future perspectives and strategies on targets for an efficient targeted delivery therapy.
    [Show full text]
  • Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis
    Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis Centers for Disease Control and Prevention Office of Infectious Diseases National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination June 2013 This document is accessible online at http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm Suggested citation: CDC. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis [online]. 2013. Available from URL: http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm Table of Contents Introduction 1 Methodology for Preparation of these Guidelines 2 The Role of Rifamycins in Tuberculosis Treatment 4 Managing Drug Interactions with Antivirals and Rifampin 5 Managing Drug Interactions with Antivirals and Rifabutin 9 Treatment of Latent TB Infection with Rifampin or Rifapentine 10 Treating Pregnant Women with Tuberculosis and HIV Co-infection 10 Treating Children with HIV-associated Tuberculosis 12 Co-treatment of Multidrug-resistant Tuberculosis and HIV 14 Limitations of these Guidelines 14 HIV-TB Drug Interaction Guideline Development Group 15 References 17 Table 1a. Recommendations for regimens for the concomitant treatment of tuberculosis and HIV infection in adults 21 Table 1b. Recommendations for regimens for the concomitant treatment of tuberculosis and HIV infection in children 22 Table 2a. Recommendations for co-administering antiretroviral drugs with RIFAMPIN in adults 23 Table 2b. Recommendations for co-administering antiretroviral drugs with RIFAMPIN in children 25 Table 3. Recommendations for co-administering antiretroviral drugs with RIFABUTIN in adults 26 ii Introduction Worldwide, tuberculosis is the most common serious opportunistic infection among people with HIV infection.
    [Show full text]
  • NPTC-Formulary Brief Acne
    Indian Health Service National Pharmacy and Therapeutics Committee Formulary Brief: Treatment of Acne vulgaris -January 2020- Background: The Indian Health Service (IHS) National Pharmacy and Therapeutics Committee (NPTC) reviewed the medical management of acne vulgaris at their January 2020 meeting. This review included topical therapies (retinoids, antibiotics, bactericidal and other anti-comedonal or anti-inflammatory agents) and oral therapies (antibiotics, isotretinoin, oral contraceptives, antiandrogens). Topical clindamycin, topical tretinoin, spironolactone, and combined estrogen-containing oral contraceptives are currently on the IHS National Core Formulary (NCF). Following clinical review, pharmacoeconomic evaluation and internal deliberation, the NPTC voted to ADD (1.) benzoyl peroxide (any topical formulation) and REPLACE topical clindamycin with (2.) combination clindamycin and benzoyl peroxide gel to the NCF. Discussion: Acne is the most common skin disorder in the United States (US), affecting 40-50 million persons of all ages. It can have significant sequelae from physical scarring, persistent hyperpigmentation, and psychological issues. Small studies focused on acne among American Indian/Alaska Native (AI/AN) populations suggest that the prevalence of acne is similar to other racial/ethnic groups in the US, but that the sequelae of scarring is significantly higher (55% in AI/AN vs. 3% among US white populations) and access to specialty care services is disproportionately low1. Acne is a chronic inflammatory disease of the pilosebaceous unit involving increased sebum production by sebaceous glands, hyperkeratinization of the follicle, colonization of the follicle by Propionobacterium acnes, and an inflammatory reaction. Acne is manifested with both non-inflammatory (open and closed comedones) and inflammatory lesions (papules, pustules, and nodules). Inflammatory acne is graded as mild, moderate, or severe based on the frequency of the various inflammatory lesions.
    [Show full text]
  • Impact of Retreatment with an Artemisinin-Based Combination On
    Muhindo Mavoko et al. Trials 2013, 14:307 http://www.trialsjournal.com/content/14/1/307 TRIALS STUDY PROTOCOL Open Access Impact of retreatment with an artemisinin-based combination on malaria incidence and its potential selection of resistant strains: study protocol for a randomized controlled clinical trial Hypolite Muhindo Mavoko1*, Carolyn Nabasumba2, Halidou Tinto3, Umberto D’Alessandro4,5, Martin Peter Grobusch6, Pascal Lutumba1 and Jean-Pierre Van Geertruyden7 Abstract Background: Artemisinin-based combination therapy is currently recommended by the World Health Organization as first-line treatment of uncomplicated malaria. Recommendations were adapted in 2010 regarding rescue treatment in case of treatment failure. Instead of quinine monotherapy, it should be combined with an antibiotic with antimalarial properties; alternatively, another artemisinin-based combination therapy may be used. However, for informing these policy changes, no clear evidence is yet available. The need to provide the policy makers with hard data on the appropriate rescue therapy is obvious. We hypothesize that the efficacy of the same artemisinin- based combination therapy used as rescue treatment is as efficacious as quinine + clindamycin or an alternative artemisinin-based combination therapy, without the risk of selecting drug resistant strains. Design: We embed a randomized, open label, three-arm clinical trial in a longitudinal cohort design following up children with uncomplicated malaria until they are malaria parasite free for 4 weeks. The study is conducted in both the Democratic Republic of Congo and Uganda and performed in three steps. In the first step, the pre-randomized controlled trial (RCT) phase, children aged 12 to 59 months with uncomplicated malaria are treated with the recommended first-line drug and constitute a cohort that is passively followed up for 42 days.
    [Show full text]
  • Clindamycin Plus Quinine for Treating Uncomplicated Falciparum Malaria: a Systematic Review and Meta-Analysis Charles O Obonyo1* and Elizabeth a Juma1,2
    Obonyo and Juma Malaria Journal 2012, 11:2 http://www.malariajournal.com/content/11/1/2 RESEARCH Open Access Clindamycin plus quinine for treating uncomplicated falciparum malaria: a systematic review and meta-analysis Charles O Obonyo1* and Elizabeth A Juma1,2 Abstract Background: Artemisinin-based combinations are recommended for treatment of uncomplicated falciparum malaria, but are costly and in limited supply. Clindamycin plus quinine is an alternative non-artemisinin-based combination recommended by World Health Organization. The efficacy and safety of clindamycin plus quinine is not known. This systematic review aims to assess the efficacy of clindamycin plus quinine versus other anti-malarial drugs in the treatment of uncomplicated falciparum malaria. Methods: All randomized controlled trials comparing clindamycin plus quinine with other anti-malarial drugs in treating uncomplicated malaria were included in this systematic review. Databases searched included: Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and LILACS. Two authors independently assessed study eligibility, extracted data and assessed methodological quality. The primary outcome measure was treatment failure by day 28. Dichotomous data was compared using risk ratio (RR), in a fixed effects model. Results: Seven trials with 929 participants were included. Clindamycin plus quinine significantly reduced the risk of day 28 treatment failure compared with quinine (RR 0.14 [95% CI 0.07 to 0.29]), quinine plus sulphadoxine- pyrimethamine (RR 0.17 [95% CI 0.06 to 0.44]), amodiaquine (RR 0.11 [95% CI 0.04 to 0.27]), or chloroquine (RR 0.11 [95% CI 0.04 to 0.29]), but had similar efficacy compared with quinine plus tetracycline (RR 0.33 [95% CI 0.01 to 8.04]), quinine plus doxycycline (RR 1.00 [95% CI 0.21 to 4.66]), artesunate plus clindamycin (RR 0.57 [95% CI 0.26 to 1.24]), or chloroquine plus clindamycin (RR 0.38 [95% CI 0.13 to 1.10]).
    [Show full text]
  • “The Red Face” and More Clinical Pearls
    “The Red Face” and More Clinical Pearls Courtney R. Schadt, MD, FAAD Assistant Professor Residency Program Director University of Louisville Associates in Dermatology I have no disclosures or conflicts of interest Part 1: The Red Face: Objectives • Distinguish and diagnose common eruptions of the face • Recognize those with potential implications for internal disease • Learn basic treatment options Which patient(s) has an increased risk of hypertension and hyperlipidemia? A B C Which patient(s) has an increased risk of hypertension and hyperlipidemia? A Seborrheic Dermatitis B C Psoriasis Seborrheic Dermatitis Goodheart HP. Goodheart's photoguide of common skin disorders, 2nd ed, Lippincott Williams & Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams & Wilkins. Seborrheic Dermatitis • Erythematous scaly eruption • Infants= “Cradle Cap” • Reappear in adolescence or later in life • Chronic, remissions and flares; worse with stress, cold weather • Occurs on areas of body with increased sebaceous glands • Unclear role of Malassezia; could be immune response; no evidence of overgrowth Seborrheic Dermatitis Severe Seb Derm: THINK: • HIV (can also be more diffuse on trunk) • Parkinson’s (seb derm improves with L-dopa therapy) • Other neurologic disorders • Neuroleptic agents • Unclear etiology 5MinuteClinicalConsult Clinical Exam • Erythema/fine scale • Scalp • Ears • Nasolabial folds • Beard/hair bearing areas Goodheart HP. Goodheart's photoguide of common skin disorders, 2nd ed, Lippincott • Ill-defined Williams & Wilkins, Philadelphia
    [Show full text]
  • Abnormal Vaginal Discharge: What Does and Does Not Work in Treating Underlying Causes
    AE_French.1104.final 10/18/04 11:03 AM Page 890 Applied Evidence N EW R ESEARCH F INDINGS T HAT A RE C HANGING C LINICAL P RACTICE Abnormal vaginal discharge: What does and does not work in treating underlying causes Linda French, MD Michigan State University, East Lansing, Mich Jennifer Horton, DO Genesys Regional Medical Center Family Practice Residency, Grand Blanc, Mich Michelle Matousek, DO Henry Ford Health System, Detroit, Mich Practice recommendations part of this article, “Abnormal vaginal discharge: Using office diagnostic testing more effectively” ■ Treat bacterial vaginosis with oral or intravagi- (JFP 2004; 53[10]:805–814), abnormal discharge nal metronidazole or with clindamycin (SOR: is more likely to be bacterial vaginosis or no A); recurrences are common (SOR: C). pathogen at all. Potential delay in diagnosis and treatment of a sexually transmitted disease is ■ Oral and intravaginal imidazoles are also a concern. Increasing resistance of Candida equally effective in the treatment of sp. to imidazoles is associated with indiscriminate candidiasis (SOR: A); alternate therapies use of over-the-counter products. for resistant cases have been little studied. ■ Oral metronidazole is the standard ■ BACTERIAL VAGINOSIS therapy for trichomoniasis (SOR: A). The standard treatment for bacterial vaginosis Oral tinidazole, newly available in the (BV) has been oral metronidazole (Flagyl) 500 mg US in 2004, should be used in resistant twice daily for 5 to 7 days. Intravaginal 0.75% cases (SOR: B). metronidazole gel (MetroGel) has been shown to be as effective as oral metronidazole (SOR: A).1,2 Oral metronidazole can cause nausea and ntifungal medications for intravaginal use abdominal pain in some patients; vaginal treat- have been available in the United States ment may be preferable for them.
    [Show full text]